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Abstract 
 
Through the potency monitoring program at the University of Mississippi supported by 
National Institute on Drug Abuse (NIDA), a total of 18108 samples of cannabis 
preparations have been analyzed over the last decade, using a validated GC/FID method. 
The samples are classified as sinsemilla, marijuana, ditchweed, hashish and hash oil (now 
referred to as cannabis concentrate).  The number of samples received over the last 5 
years has decreased dramatically due to the legalization of marijuana either for medical 
or recreational purposes in many US states. The results showed that the mean Δ9-THC  
concentration has increased dramatically over the last ten years, from 8.9% in 2008 to 
17.1% in 2017. The mean Δ9-THC:CBD ratio also rose substantially from 23 in 2008 to 
104 in 2017. There was also marked increase in the proportion of hash oil samples 
(concentrates) seized (0.5% to 4.7%) and their mean Δ9-THC concentration (6.7% to 
55.7%) from 2008-2017. Other potency monitoring programs are also present in several 
European countries such as the Netherlands, United Kingdom, France, and Italy. These 
programs have also documented increases in Δ9-THC concentrations and Δ9-THC:CBD 
ratios in cannabis. These trends in the last decade suggest that cannabis is becoming an 
increasingly harmful product in the USA and Europe. 
 
Key Words Cannabis. Potency Monitoring. Sinsemilla. Marijunna. Hashish. Hash oil. 
Concentrates. Δ9- THC. CBD. CBN. CBG  
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Introduction 
 
The use of psychoactive substances by humans can be traced back to ancient times. First 
documentation of cannabis use was in 2,700 B.C.; however, archeological and historical 
data from China indicate that Cannabis sativa was cultivated for fibers since 4,000 B.C. 
in Central Asia and North-Western China [44, 51, 60]. Cannabis use, and ultimately 
cultivation, subsequently spread throughout the world, specifically in India (ca. 1,600 
B.C.), Egypt (1,550 B.C.), the Near and Middle East (ca. 900 B.C.), Europe (ca. 800 
B.C.), South-East Asia (100–200 A.D.), sub-Saharan Africa (1,000–1,100 A.D.), and the 
Americas (1,500–1,900 A.D.). 
 
 The Chinese used cannabis fibers to manufacture textiles, paper and ropes, while 
the fruit was used as food. Medicinal use of cannabis started around the same time as its 
use as an agricultural crop, with uses that included rheumatic pain, intestinal constipation 
and malaria. Reports of the medicinal uses of cannabis first appeared in the Chinese 
pharmacopoeia, Shen-nung Pen Ts’ao ching (Divine Husbandman’s Materia Medica), in 
the first century A.D. [1, 36, 60]. According to the pharmacopoeia, ma-fen, the flowers of 
the female plant, provided the most medicinal value, being prescribed for menstrual 
fatigue, rheumatism, malaria, beriberi, constipation and forgetfulness. The 
pharmacopoeia however, warned that ingesting too many cannabis seeds “will produce 
visions of devils… over a long term, it makes one communicate with spirits and lightens 
one’s body…” [32]. This is the first known documented reference to the psychoactive 
properties of cannabis. 
 
 In India, cannabis was widely used as a medicine and a recreational drug; 
however, authorities differ on the exact date of its introduction into the sub-continent. 
Cannabis use in Ancient India was claimed in the Atharva Veda ca. 1,600 B.C. [53], 
while others have questioned whether references to cannabis in Indian literature are 
reliable prior to 1,000 A.D. [39, 51]. There are three popular preparations available, each 
providing a range of psychoactivity. Three popular preparations are available providing a 
range of psychoactivity: “Bhang”, prepared from dry leaves without any flowers, was the 
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weakest preparation, followed by “Ganja”, prepared from the flowers of female plants, 
and “Charas”, made from the highly potent resin that covers female flowers. Medicinal 
indications included analgesic, anti-convulsant, hypnotic, tranquilizer, anesthetic, anti-
inflammatory, anti-biotic, anti-parasitic, anti-spasmodic, digestive, appetite stimulant, 
diuretic, aphrodisiac or anaphrodisiac (anti-aphrodisiac), anti-tussive, and expectorant 
[25]. 
 
 The ancient Egyptians also used cannabis as a medicine. A series of ancient 
writings on stone and medical papyri, including the oldest surviving original document 
which mentions cannabis, the Ebers papyrus (ca. 1,550 B.C.), describe the medicinal use 
of cannabis for glaucoma, gynecological disorders, migraines, and anti-inflammatory and 
analgesic effects. However, the limited reference to cannabis and the absence of 
therapeutic information indicate that it was not frequently used medicinally. This is 
possibly due to the fact that cannabis was not native to Egypt, and therefore only 
available in limited supply. Also, these documents did not explicitly refer to the 
psychoactive effects of cannabis [45, 56].  
 
 The Scythians, an Ancient Iranian people who originated from Central Asia, 
introduced cannabis to Europe before the Christian Era (C.E.), as described by the Dorian 
Greek historian Herodotus of Halicarnassus (430–424 B.C.) [32, 39]. The Greeks and 
Romans also used medical cannabis, although it appears that they did not use the 
flowering tops, only the seeds and roots of the plant to treat minor ailments [7]. 
 
 Cannabis has been cultivated and used in sub-Saharan Africa, especially Eastern 
and Southern Africa, since at least the fifteenth century, when it was probably introduced 
by Arab merchants establishing trading posts on the continent (1,100–1,200 A.D.). 
Research indicates that the San and Khoikhoi people, the earliest inhabitants of Southern-
Africa, used “dagga” (slang for cannabis in South Africa) before 1,500 A.D., i.e., before 
the first contact between Europeans and native Africans. In Africa, the plant was used for 
snake bites, to facilitate childbirth, malaria, fever, blood poisoning, anthrax, asthma, and 
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dysentery. Present-day uses include treatment of indigestion and high blood pressure, as 
well as to deworm horses and donkeys [15-17, 37]. 
  
 In America, the cannabis use probably began in South America when the Spanish 
introduced the plant to Chile (1,545 A.D.). However, bones of Peruvian mummies dated 
from 200 to 1,500 A.D. were shown to contain cannabinoids [46], indicating contact 
between South America and Asia or Egypt before the arrival of Christopher Columbus 
(1451–1506) in 1,545 A.D.[42]. It is generally accepted that cannabis was imported to 
Brazil in the early sixteenth century by slaves from Western African countries, 
particularly to Angola, Congo, Senegal and the Guinea Coas [3, 38, 56]. 
 
 Although it is not known exactly when the psychotropic properties of cannabis 
were discovered in North America, evidence suggests that Louis Hébert (1575–1627), the 
apothecary (pharmacist) of Samuel de Champlain (1580–1635), a French navigator, 
cartographer and explorer, introduced cannabis to American settlers in 1606. Initially 
hemp was only used in the production of rope, sails, and clothing; the medicinal use of 
cannabis across North America started between 1840 and 1900 [12]. It was prescribed for 
tetanus, epilepsy, rheumatism, rabies, and as a muscle relaxant. During this time, 
cannabis preparations were sold freely in pharmacies of Western countries. 
 
 The American market produced numerous cannabis-containing home remedies in 
the late nineteenth and early twentieth centuries [2, 25]. Companies such as Merck, 
Burroughs-Wellcome, Bristol-Meyers Squibb, Parke-Davis and Eli Lilly marketed 
various cannabis extracts and tinctures.  However, cannabis was dropped from the British 
Pharmacopeia in 1932 and from the United States Pharmacopeia in 1941 [8]. Reasons for 
this decline included variable repeatability, efficacy and potency, short and unpredictable 
shelf-life, irregular response to oral administration, availability of potent opiates and 
synthetic alternatives, popularity of parenteral medicines, commercial pressures, and 
concern about recreational use. These concerns led to national and international laws 
restricting the medicinal use and research of cannabis. Currently, cannabis is highly 
regulated in the USA at the federal level.  
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 In spite of strict laws, cannabis use is still prevailing in the United States and 
marijuana is the most widely used illicit drug. At the time of writing this manuscript, 
cannabis has been legalized for recreational use in nine US states and as a medicine in 31 
US states. It is probably too early to predict the long term public health implications of 
these changes [31]. However, one key aspect of cannabis use that can be regularly 
monitored is the potency of cannabis preparations. The cannabis plant bio-synthesizes at 
least 144 cannabinoids [33], and the most abundant of these are 9-tetrahydrocannabinoid 
(9-THC) and cannabidiol (CBD). 9-THC is responsible for the intoxicating effects of 
cannabis, and experimental studies show that it can cause memory impairment, anxiety 
and transient psychotic-like symptoms in a dose-dependent manner [13]. CBD is non-
intoxicating and has been found to offset several, harmful effects of 9-THC, including 
memory impairment and psychotic-like symptoms [4, 24, 43]. As a result, the doses of 
9-THC and CBD, and their relative ratio, are important factors in determining the level 
of harm an individual may experience [6, 11, 23]. Data from naturalistic studies show 
that cannabis users only partially adapt their smoking behavior to variation in 9-THC 
concentrations, implying that higher potency cannabis preparations will deliver larger 
doses of 9-THC [28, 55]. Moreover, a growing number of studies report that higher 
potency cannabis preparations are associated with adverse health outcomes, including 
elevated symptoms of cannabis use disorder [5, 30, 41], increased treatment admissions 
for cannabis problems [29], higher risk of developing psychosis [14], and increased risk 
of relapse to psychosis [52]. Increases in cannabis potency could therefore have 
important implications for the health effects of cannabis use, especially among 
adolescents who may be more vulnerable to cannabis harms [57].  
 
 In the United States, early evidence suggests that extremely potent cannabis 
concentrates (such as Butane Hash Oil) have risen in popularity in recent years. Within 
two years of legal sale in Washington State (2014-2016), these were estimated to account 
for 21% of the entire retail market and had a mean potency of 69% 9-THC [54]. 
However, the extent to which these products are available in illicit markets across the 
United States is currently unknown. It is very important to monitor the potency of the 
  
 
 7 
confiscated biomass and cannabis products as a measure of what is actually being sold 
and consumed on the illicit market [26]. We previously reported that cannabis potency in 
the United States increased from ~4% in 1996 to ~12% in the year 2014 [22]. In this 
article, we report new trends in cannabis potency in the United States over the last decade 
(2008 to 2017) and provide an overview of recent trends in cannabis potency in Europe.  
 
Potency Monitoring Program in the US  
 
Materials and Methods 
 
Sample Acquisition and Identification  
Our laboratories at the University of Mississippi receive confiscated samples from the 
Drug Enforcement Administration (DEA) laboratories under agreement with the National 
Institute on Drug Abuse (NIDA). These DEA laboratories include Special Testing 
Research Laboratory (STRL), Northeast Regional Laboratory (NRL), Mid-Atlantic 
Regional laboratory (MARL), North Central Regional laboratory (NCRL), South Central 
Regional Laboratory (SCRL), Southwest Regional laboratory (SWRL), and Western 
Regional laboratory (WRL).  The received samples can be classified into three 
categories: cannabis, hashish, and hash oil.  Cannabis samples are further classified into 
two categories, based on their physical characteristics: marijuana or sinsemilla. Marijuana 
is the dried buds with leaves, stems, and seeds typically grown outdoors for illicit drug 
use, mainly of female cannabis plants.    
  
 Sinsemilla consists of buds of unfertilized female plants, typically without seeds, 
mainly grown indoors. Ditchweed consists of a mixture of a fiber type male and female 
wild cannabis grown in the Midwestern states. Hashish is a black, green or golden 
colored resin (based on the purity and method of preparation) obtained from the buds of 
the female plants and shaped as balls, sticks or slabs. Hash oil (referred to as 
concentrates) is a liquid or semi-solid cannabis product obtained by the solvent extraction 
of cannabis biomass (usually from the intermediate-type). It is black to dark green in 
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color with a strong marijuana smell. All samples received are stored at room temperature 
(17± 4 ºC) and are analyzed shortly after receipt.       
 
Sample Preparation  
 Cannabis (Marijuana, sinsemilla or ditchweed):  Samples were manicured by 
sieving for the removal of the stems and seeds. Each of the two 100.0 mg portions of the 
manicured material were each extracted with 3 mL of the internal standard solution [4-
Androstene-3,17-dione (IS), at 1 mg/mL in CHCl3/MeOH (1:9)] at room temperature for 
1 h. The extract was filtered and the filtrate analyzed by gas chromatography with flame 
ionization detection (GC/FID).  
Hashish: A single-edge razor blade was used to scrape 100 mg (in duplicate) from the 
block of hashish and extracted following the above procedure for cannabis preparations. 
Hash oil (concentrates): Two 100 mg aliquots were extracted with 4.0 mL of IS (1.0 
mg/mL ethanol) at room temperature for 2 h and sonicated for 5 min. Then, 20 mL of 
ethanol was added to each sample and sonicated briefly. The extract was filtered and 
transferred to GC vials for analysis. 
 
GC-FID Analysis  
All samples were analyzed using a Varian 3380 gas chromatograph equipped with 
a Varian CP-8400 automatic liquid sampler, dual capillary injectors, and dual flame 
ionization detectors (GC/FID).  The column was a 15 m X 0.25 mm DB-1, 0.25μ film. 
Data was recorded with a Dell Optiplex GX1 computer with Microsoft Windows 98 and 
Varian Star (version 5.31) workstation software. Technical grade helium was used as the 
carrier gas.  A high capacity oxygen trap was located in the helium line.  Helium was 
used as the detector make-up gas.  Hydrogen and compressed air were used as the 
combustion gases.  The method was previously reported [40] and used for the 
quantitative analysis of seven main cannabinoids in the received samples, namely 9-
tetrahydrocannabinol (9-THC), cannabidiol (CBD), cannabinol (CBN), cannabichromen 
(CBC), 8-tetrahydrocannabinol (8-THC), cannabigerol (CBG), and 9-
tetrahydrocannabivarin (9-THCV). This analytical method is fast (12 min./run), 
accurate, and precise using a single column. Direct injection of cannabis extract into the 
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GC results in decarboxylation of the cannabinoid acids, therefore measuring the 
concentration of the total cannabinoids (free and acids).  Quantitative values are based on 
peak area ratios relative to the area of the internal standard peak (4-Androstene-3,17-
dione) contained in the extraction solvent. 
  
Calculation of Cannabinoid Concentration 
Quantitative values of potency (% dry weight) are computer-generated based on 
the analyte/internal standard area ratio, with each cannabinoid having a response factor of 
1.0. The concentration of each cannabinoid in the samples is calculated from the 
following equation:  
% Analyte = (Area Analyte/Area Internal Standard) x (amount of IS*/100 mg) x 100 
* The amount of IS is 3 mg in cannabis and hashish samples and 4 mg in hash oil    
 
Results and Discussion 
 
There were a total of 18,674 samples seized between January 1, 2008 and June 
31, 2018 by DEA regional laboratories, out of which 18,108 samples (96.9%) were 
analyzed in our laboratory (Table 1). As seen in Table 1, the number of seized samples 
decreased dramatically from 2882 in 2008 to 642 samples in 2017. Confiscated samples 
are classified as cannabis, hashish or hash oil (concentrates).  Cannabis is plant material 
which is further classified into sinsemilla, marijuana and ditch weed. Table 1 and Fig. 1 
show the number of samples analyzed by category for each year from 2008-2017, with 
cannabis representing more than 95.0% of the samples analyzed. As can be seen in Table 
1, the most predominant type of seized cannabis is the sinsemilla form, representing 
58.6% of all seizures, followed by marijuana (36.1%), and ditch weed (0.6%).  Hash oil 
(concentrates) seizures gradually increased from 0.5% in 2008 to 4.7% in 2017 with the 
highest number in 2016 (5.8%). The number of hashish samples represented 1.4-5.1% of 
seizures with no observable trend over time.  
  
 The mean concentration of Δ9-THC of all the analyzed samples increased from 
8.9% in 2008 to 17.1% in 2017 (Table 2, Fig. 2).  The highest mean concentration was 
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recorded in 2017 (17.1%), with no change between 2012-2016. Sinsemilla and marijuana 
showed the same trend of increasing potency over the last 10 years. The highest 9-THC 
content was achieved in 2017 for both sinsemilla and marijuana with potencies of 17.8% 
and 9.4% 9-THC, respectively (Table 2, Figure 3). The marijuana mean 9-THC 
concentration showed a slight increase in the last decade from 6.0% in 2008 to 7.3% in 
2016. Since ditch weed represents only 0.6% of the analysed samples and the average 
THC content is 0.4% ± 0.2%, the potency of both sinsemilla and marijuana largely 
determine the overall potency of confiscated cannabis over the last decade (Table 2, Fig. 
2-3). Sinsemilla samples showed much higher potency than marijuana, which is in 
agreement with previously published data [19-22, 40].  The 9-THC/CBD ratio across all 
samples tested during the period of this report increased dramatically from 23 in 2008 to 
104 in 2017 (Fig. 4) , which reflects an increasing trend of the growth and consumption 
of high 9-THC/low CBD cannabis material over the last decade.    
 
 Trends in the 9-THC content of hash and hash oil over time are shown in Table 2 
and Figure 5. The mean 9-THC concentration in confiscated hashish samples between 
2008 and 2014 increased from 22.8 % to 30.3%, dropped in 2015 (17.6%) and 2016 
(15.5%), and achieved the maximum concentration in 2017 (45.9%). The hash oil 
(concentrates) mean 9-THC content showed a substantial increase in the last decade. It 
increased from 6.7% in 2008 to 53.5% in 2012, stabilized at 50% in 2013 and 2014, then 
dropped significantly in 2016 (37.9%) and sharply increased to 55.7% in 2017 (Table 2 
and Figure 5).  
 
 The average concentration of cannabinoids other than 9-THC in all of the 
confiscated samples (cannabis, hashish and hash oil) from 2008 to 2017 is presented in 
tables 3-6. These cannabinoids include cannabichromene (CBC), cannabidiol (CBD), Δ8 
–tetrahydrocannabinol (Δ8- THC), cannabinol (CBN), cannabigerol (CBG), and Δ9 –
tetrahydrocannabivarin. The mean concentration of these minor cannabinoids is relatively 
higher in hash and hash oil compared to the cannabis samples. CBD is the major 
cannabinoid in ditch weed and in the intermediate-type, which contains both THC and 
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CBD in moderate level, cannabis plant material, from which hashish is made. Hash oil is 
predominantly made from high potency (high 9-THC) cannabis plant material. The 
average concentration of CBD in hash and hash oil in the last decade showed significant 
fluctuation with a high Standard Deviation (SD) almost every year (Tables 5 and 6). After 
9-THC and CBD, the most prevalent cannabinoids were identified to be CBN and CBG. 
The ratio of CBN concentration to 9-THC reflects, to a certain degree, the age of the 
sample, with higher concentrations of CBN indicating older material [50]. The 
concentrations of both CBN and CBG are higher in hashish and hash oil than in cannabis. 
The mean concentration of CBN in hash oil ranged from approximately 1.5% to 3%, 
while the CBG concentration ranged from approximately 0.15% to 1.7%, with substantial 
fluctuation.  The CBN concentration in hashish was higher than hash oil, reaching almost 
6% in 2016, but generally around 2-3%. The CBG concentration, on the other hand, was 
generally less than 1% in hashish.   
 
Potency Monitoring Programs in Europe 
  
 Consistent with our findings in the USA, a meta-analysis performed on 21 
different studies worldwide, containing 75 observations from 1979 to 2009 on mean 9-
THC levels in herbal cannabis samples, revealed a consistent increase in cannabis 
potency worldwide, with a mean increase of 0.21% 9-THC each year [9]. More recently, 
the data collected and submitted between 2006-2016 from the 28 European Union 
Member States, Norway, and Turkey to the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) was analyzed [27]. Mean 9-THC concentrations increased 
from 5.00% to 10.22% in herbal cannabis. Cannabis resin increased in mean 9-THC 
concentration from 8.14% to 17.22%. Moreover, the increase in the potency of cannabis 
resin was characterized by a quadratic time trend in which there was minimal change 
from 2006-2011, followed by rapid increase in 9-THC from 2011-2016 [27]. The recent 
increase in European resin potency has been attributed to a new form of resin produced 
from cannabis containing high 9-THC and little CBD, which may be due to the 
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replacement of landrace crops by newer high 9-THC strains in Morocco [10]. Findings 
in specific European countries are given below. 
 
 
The Netherlands 
 
 The Netherlands has the most comprehensive cannabis monitoring program in 
Europe, conducted by the Trimbos Institute. Each year, at least 50 retail outlets (‘coffee 
shops’) are visited at a fixed time of year, to control for seasonal variation in potency.  
Test purchases are made for a range of different products using a standardized protocol. 
The retail outlets are selected from a national list each year using randomized sampling. 
A study reveals that the mean percentage of 9-THC in domestically grown herbal 
cannabis (Nederwiet) increased from 8.6% to 20.4% from 2000 to 2004 [51]. 
Additionally, hashish made from domestically grown herbal cannabis (Nederhasj) 
contained an increasing content of 9-THC from a mean of 20.7% to 39.3%; the mean 
9-THC content in imported hashish rose from 11.0% to 18.2%. The mean 9-THC 
content for imported herbal cannabis rose at a smaller rate, from 5.0% in 2000 to 7.0% in 
2004. Only imported hashish contained significant CBD, ranging from 3.7% to 13.5% 
[47].  
 
In a more recent study from 2005 to 2015, the mean 9-THC content of cannabis 
products in the Netherlands has decreased slightly from 2005-2015, with an overall 
decline of 0.22% each year. The most popular form of Nederwiet decreased from a mean 
9-THC concentration of 17.8% to 15.3%, and imported herbal cannabis decreased from 
a mean of 6.7% to 4.8% 9-THC. However, the content of 9-THC in imported hashish 
remained relatively stable, starting from 16.9% and ending at 17.8%; Nederhasj increased 
from a mean of 20.0% to 31.6%. As in the previous study [47], imported hashish was the 
only type of cannabis with significant levels of CBD, and these did not change from 
2005-2015.  
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United Kingdom 
 
 A study in England assessed the potency of 451 cannabis samples seized during 
2004-2005 by police from five different constabularies [48]. The median 9-THC content 
of imported herbal cannabis, sinsemilla and resin (hashish) samples were reported to be 
2.1%, 13.9% and 3.5%, respectively. A subsequent study of 2,921 cannabis samples from 
23 constabularies across England and Wales in 2008 found that the median 9-THC 
content of imported herbal, sinsemilla and resin were 9.0%, 15.0%, and 5.0%, 
respectively [34]. More recently, a study of 995 cannabis samples [49] from the same five 
constabularies as the 2004-2005 study [48] found similar potencies to those in the 
original study for herbal forms of cannabis, with median 9-THC concentrations of 3.5% 
(imported herbal) and 14.2% (sinsemilla). However, cannabis resin had increased in 
potency from a mean 9-THC concentration of 3.7% in 2005 to 6.3% in 2016. Two 
samples of hash oil (51% 9-THC and < 1% CBD) and a small number of butane hash oil 
samples (ranging from 73-83% 9-THC, with < 1% CBD) were also provided by 
constabularies, showing that cannabis concentrates may be emerging in the illicit UK 
market.  Cannabis resin was the only preparation to contain significant levels of CBD in 
England and Wales. However, CBD concentrations in resin dropped from a mean of 
4.3% in 2004-2005 to 2.3% in 2016. The most substantial changes occurring in the UK 
cannabis market have been the increase in the market share of sinsemilla. Within the five 
constabularies sampled in England at three recent time points, the market share of 
sinsemilla increased from 50.6% in 2005 to 84.5% in 2008, and 93.6% in 2016. As a 
result, the 9-THC:CBD ratio of all samples increased during this time, consistent with 
recent trends in the USA. 
 
Italy 
 
A study published by Zamengo et al. (2014) [59] and an update by the same 
authors in 2015 [58] provide information on trends of cannabinoid concentrations in the 
Venice area based on a total of 4,962 samples. Among all of the samples, the mean 9-
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THC increased over time from 6.84% in 2010, 6.87% in 2011, 8.53% in 2012, and 9.57% 
in 2013. For all of the herbal preparations, the mean 9-THC increased from 6.17% in 
2010, 5.75% in 2011, 7.51% in 2012, and 9.07% in 2013. There was also evidence for an 
increasing 9-THC concentration in resin, from 7.58% in 2010, 7.89% in 2011, 10.31% 
in 2012, and 10.69% in 2013. Across all of the cannabis preparations, there were 
decreases in the ratio of CBD:9-THC and in CBN:9-THC. The mean CBD:9-THC 
ratios were 0.458 in 2010, 0.401 in 2011, 0.317 in 2012, and 0.273 in 2013. The mean 
CBN:9-THC ratios were 0.115 in 2010, 0.192 in 2011, 0.085 in 2012 and 0.069 in 2013. 
These changes were attributed to an increase in the market share of cannabis preparations 
from indoor and domestic cultivation (e.g. sinsemilla and new methods of resin 
production using high 9-THC/low CBD plant material) [58].    
 
France 
 
In France, a major study published by Dujourdy and Besacier presented trends in 
cannabis potency over the last 25 years, from 1992 to 2016, from five French forensic 
police laboratories [18]. For herbal cannabis, the authors identified three different time 
periods based on the data collected. From 1995 to 2002, 9-THC concentrations remained 
below 7.6% (the overall mean from 1995-2016), from 2003 to 2009, they fluctuated 
around 7.6%, and from 2010 to 2016, they reached a peak of 13%. The authors also 
reported an increase in the 9-THC:CBD ratios according to the classification system of 
Hillig and Mahlberg [35], with evidence that from 2010, plants with the ‘chemotype 1’ 
(log 9-THC:CBD ratio > 1) were predominant over ‘chemotype 2’ (log 9-THC:CBD 
ratio between -0.6 and 1). According to Ross and ElSohly, the CBN:9-THC ratio is an 
indicator of freshness of the sample [50]. In this study, the overall mean of CBN:9-THC  
ratio in herbal cannabis was reported to be 0.06 which suggests that the material was 1 to 
2 years old. Whereas, this ratio was found to be lower in the samples from 2009 till mid-
2016, showing that these samples were relatively fresher (less than 1 year). 
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There was also strong evidence of increasing potency of cannabis resin in France 
[18]. As with herbal cannabis, three distinct time periods were evident. From 1992 to 
2000, the mean 9-THC concentration was 6.9%, which rose to 9.2% from 2001-2010, 
and then increased two-fold to 18.2% from 2011-2016. The authors reported that since 
2011, two different types of resin samples have been available: “classic” resin with a 
mean of 13% 9-THC and a new high potency form of resin with a mean of 26% 9-
THC.  This new higher potency form of resin increased from 2011-2016; almost 75% of 
all resin samples in 2016 were in this category. Across all resin samples, CBD 
concentrations remained relatively stable from 1992-2016, with a mean of 4%.  However, 
an inspection of 9-THC/CBD ratios revealed increases over a time, rising from a median 
of approximately 2 in 2009 to 6 in 2016. In 2004 and 2009, these ratios (9-THC:CBD) 
typically ranged from 0.5 to 5; however, in 2015, the range had extended considerably to 
0.5-31, supporting the emergence of new resin products containing high 9-THC and low 
CBD. 
 
Conclusion 
 
In the last decade, cannabis potency (9-THC) and the 9-THC:CBD ratios have 
continued to rise in the United States and Europe. These trends can be predominantly 
explained by increases in the market share of sinsemilla, the rising potency of sinsemilla 
and imported herbal cannabis, and new methods of resin production resulting in higher 
9-THC and lower levels of CBD. New, extremely potent forms of hash oil 
(concentrates) are becoming more prevalent and potent in the USA but are only just 
beginning to emerge in Europe. The data indicates that cannabis potency has continued to 
rise in Europe, in line with trends in the USA. These trends may indicate that people who 
use cannabis are at greater risk of harm than in previous years. 
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Table 1 Number of analyzed samples (n) per year 
 
Year Seized 
Total number 
Seized 
Total number 
Analysed 
Number of Cannabis samples analyzed Number of analyzed 
Hashish samples 
 
Number of analyzed 
Hash oil samples 
Sinsemilla Marijuana Ditchweed 
n % n % n % n % n % 
 
2008 
 
2882 2776 
 
1313 
 
47.3% 
 
1354 
 
48.8% 
 
33 
 
1.2% 
 
62 
 
2.2% 
 
14 
 
0.5% 
2009 3159 3083 1533 49.7% 1462 47.4% 40 1.3% 42 1.4% 6 0.2% 
2010 2812 2756 1462 53% 1183 42.9 21 0.8% 79 2.9% 11 0.4% 
2011 2540 2484 1615 65.0% 722 29.1% 6 0.2% 120 4.8% 21 0.9% 
2012 2326 2264 1550 68.5% 548 24.2% 2 0.1% 116 5.1% 48 2.2% 
2013 1329 1302 958 73.4% 269 20.7% 2 0.1% 41 3.1% 32 2.5% 
2014 1058 1049 777 74.1% 187 17.8% 1 0.1% 23 2.2% 61 5.8% 
2015 1086 1074 690 64.3% 303 28.2% 5 0.5% 23 2.1% 53 4.9% 
2016 840 814 421 51.7% 326 40.1% 2 0.2% 18 2.2 47 5.8% 
2017 642 506 292 57.7% 183 36.2% 0 0 7 1.4% 24 4.7% 
2008-2017 18674 18108 10611 58.6% 6537 36.1% 112 0.6% 531 2.9% 317 1.8% 
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Table 2 Mean and SD of Δ9-THC concentration (%) by type of sample and year   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year 
All Cannabis  
All Cannabis 
 
Hashish 
 
Hash oil Sinsemilla Marijuana Ditchweed 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
2008 8.9 6.7 11.5 6.1 6.0 3.9 0.4 0.3 6.0 3.4 22.8 19.3 6.7 9.3 
2009 8.3 6.2 10.8 6.1 5.7 4.2 0.4 0.3 5.6 3.5 21.3 15.3 8.9 9.6 
2010 10.0 7.7 12.7 6.1 5.7 4.4 0.5 0.3 6.3 3.6 22.8 16.5 38.3 30.1 
2011 12.3 8.9 13.6 6.2 5.6 3.1 0.5 0.2 6.6 3.2 30.0 15.1 37.0 26.2 
2012 14.1 11.3 14.5 6.4 6.1 3.7 0.65 0.1 7.1 3.4 31.7 19.1 53.5 25.5 
2013 13.4 10.2 13.6 5.9 6.3 3.1 0.5 0.1 6.8 3.0 29.3 16.4 50.0 26.6 
2014 14.6 13.5 13.5 6.4 5.8 3.7 0.2 --- 6.5 5.1 30.3 23.7 50.8 27.3 
2015 13.4 13.2 12.7 6.1 6.8 3.2 0.4 0.3 6.6 3.2 17.6 20.1 56.3 24.9 
2016 13.2 10.8 15.0 5.6 7.3 3.4 0.8 0.1 7.7 3.0 15.5 14.3 37.9 26.6 
2017 17.1 12.9 17.8 5.1 9.4 4.7 0 0 13.6 4.9 45.9 26.6 55.7 24.7 
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               Table 3 Mean and SD of CBD concentration (%) by type of sample and year   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year 
 
All samples 
 
Cannabis 
 
Hashish 
 
Hash oil 
Mean SD Mean SD Mean SD Mean SD 
2008 0.41 1.08 0.37 0.96 2.22 2.97 0.20 0.40 
2009 0.33 0.90 0.35 0.86 1.26 2.10 0.34 0.56 
2010 0.28 0.69 0.27 0.66 0.25 0.60 0.65 1.24 
2011 0.23 0.59 0.22 0.56 0.49 0.98 0.44 1.02 
2012 0.22 0.71 0.20 0.56 0.53 1.41 0.66 2.36 
2013 0.18 0.59 0.16 0.56 0.36 0.56 0.46 1.33 
2014 0.23 0.99 0.15 0.61 1.38 2.58 1.13 2.70 
2015 0.21 0.70 0.18 0.50 0.95 1.78 0.57 1.84 
2016 0.35 2.37 0.19 0.77 0.64 0.66 2.82 9.11 
2017 0.15 0.66 0.14 0.66 0.39 0.57 0.39 0.78 
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Table 4 Mean cannabinoid concentration in cannabis samples by year 
Year CBC CBD Δ9-THC Δ8-THC CBN CBG THCV 
2008 0.26±0.18 0.37±0.96 6.0±3.4 0.00 0.32±0.42 0.32±0.35 0.09±0.14 
2009 0.26±0.25 0.35±0.86 5.6±3.5 0.01±0.04 0.37±0.44 0.28±0.35 0.08±0.11 
2010 0.26±0.20 0.27±0.66 6.3±3.6 0.05±0.25 0.43±0.43 0.31±0.33 0.08±0.10 
2011 0.25±0.24 0.22±0.56 6.6±3.2 0.06±0.10 0.45±0.45 0.42±0.96 0.09±0.13 
2012 0.24±0.14 0.20±0.56 7.1±3.4 0.08±0.11 0.56±0.46 0.43±0.34 0.09±0.10 
2013 0.26±0.15 0.16±0.56 6.8±3.0 0.08±0.12 0.63±0.49 0.46±0.36 0.10±0.15 
2014 0.22±0.12 0.15±0.61 6.5±5.1 0.07±0.12 0.65±0.57 0.43±0.32 0.08±0.12 
2015 0.22±0.11 0.18±0.50 6.6±3.2 0.07±0.11 0.75±057 0.47±0.32 0.08±0.10 
2016 0.23±0.14 0.19±0.77 7.7±3.0 0.08±0.12 0.73±0.53 0.46±0.32 0.08±0.11 
2017 0.28±0.19 0.14±0.66 13.6±4.9 0.13±0.16 0.62±0.44 0.54±0.37 0.09±0.08 
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Table 5 Mean cannabinoid concentration in hashish samples by year  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year CBC CBD Δ9 -THC Δ8 -THC CBN CBG THCV 
 
2008 0.91±0.62 2.22±2.97 
 
22.8±19.3 0.00 2.19±1.69 0.76±0.67 0.37±0.59 
2009 0.92±0.89 1.26±2.10 21.3±15.3 0.06±0.13 2.94±2.92 0.41±0.44 0.17±0.13 
2010 0.73±0.63 0.25±0.60 22.8±16.5 0.41±0.39 2.28±1.99 0.62±0.69 0.36±0.27 
2011 1.12±0.70 0.49±0.98 30.0±15.1 0.24±0.20 2.90±2.23 0.70±0.58 0.23±0.16 
2012 0.82±0.51 0.53±1.41 31.7±19.1 0.33±0.27 2.79±2.37 0.71±0.66 0.21±0.16 
2013 0.72±0.31 0.36±0.56 29.3±16.4 0.28±0.24 2.44±1.92 0.83±0.72 0.21±0.18 
2014 0.97±0.59 1.38±2.58 30.3±23.7 0.33±0.29 3.05±3.06 0.90±0.70 0.24±0.20 
2015 0.51±0.28 0.95±1.78 17.6±20.1 0.15±0.10 2.60±2.30 0.56±0.60 0.14±0.17 
2016 0.72±0.45 0.64±0.66 15.5±14.3 0.14±0.16 5.70±3.99 0.85±2.26 0.07±0.07 
2017 0.99±0.57 0.39±0.57 45.9±26.6 0.80±0.23 2.88±1.91 1.66±1.16 0.36±0.17 
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Table 6 Mean cannabinoid concentration in hash oil (concentrates) samples by year  
Year CBC CBD Δ9 -THC Δ8 -THC CBN CBG THCV 
2008 0.33±0.53 0.20±0.40 6.7±9.3 0.00 1.41±3.06 0.14±0.21 0.13±0.19 
2009 0.21±0.34 0.34±0.56 8.9±9.6 0.08±0.20 3.28±5.82 0.26±0.33 0.24±0.29 
2010 0.86±0.63 0.65±1.24 38.3±30.1 0.24±0.20 2.96±2.58 0.51±0.51 0.21±0.37 
2011 0.95±0.65 0.44±1.02 37.0±26.2 0.22±0.17 2.52±3.34 0.86±0.80 0.32±0.53 
2012 0.96±0.66 0.66±2.36 53.5±25.5 0.50±0.34 2.73±2.24 1.05±0.67 0.33±0.29 
2013 1.06±0.75 0.46±1.33 50.0±26.6 0.37±0.28 2.18±1.51 1.05±0.72 0.27±0.16 
2014 0.92±0.65 1.13±2.70 50.8±27.3 0.33±0.37 2.17±2.06 1.29±1.09 0.43±0.62 
2015 1.14±0.76 0.57±1.84 56.3±24.9 0.53±0.35 2.84±2.90 1.60±1.13 0.29±0.15 
2016 1.02±0.66 2.82±9.11 37.9±26.6 0.48±0.48 3.01±3.18 1.29±1.05 0.25±0.23 
2017 1.13±0.65 0.39±0.78 55.7±24.7 0.80±1.17 2.88±2.50 1.66±0.86 0.36±0.44 
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Fig 1 Number of cannabis seizures by type and year (2008-2017) 
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Fig 2 Mean Δ9-THC concentration for all samples seized from 2008 to 2017 
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Fig. 3 Mean Δ9-THC concentration for sinsemilla and marijuana samples seized from 2008 to 
2017 
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Fig. 4 Ratio of the mean concentration of 9-THC to CBD in across all samples by year  
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Fig 5 Mean Δ9-THC concentration for hashish and hash oil (concentrates) samples seized from 
2008 to 2017   
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